Agomelatine is the world's first melatonin receptor MT1 and MT2 agonist antidepressant. It was developed by the French company Servier and is suitable for the treatment of severe depressive episodes in adult patients. We know that melatonin is an endogenous neurohormone, which is secreted only by the anterior pituitary of the pineal gland at night, and acts on the melatonin receptors concentrated in the suprachiasmatic nucleus (SCN) of the hypothalamus.Participate in the regulation of the circadian rhythm of mammals. It is a well-known guardian of time in the body and corrects the biological clock regulated by the external circadian cycle.
Agomelatine is a new antidepressant with selective agonist actions at melatonin receptors and selective antagonist action at serotonin 5HT-2C receptors.It does not affect the uptake of serotonin, noradrenaline or dopamine.Agomelatine can help regulate your'body clock' (circadian rhythm) with positive benefits on mood and sleepin depression Agomelatine is used in the treatment of depression or to help prevent depression returning, and isonly available with a doctor's prescription. The symptoms of depression vary from one person toanother, but commonly include persistent sadness, loss of interest in favourite activities, feelings of worthlessness, sleep problems, feeling of being slowed down, feelings of anxiety or changes in appetite and weight. Changes in your daily sleep and appetite patterns are examples of disturbances of your body clock that occur commonly indepression.
1.Major depressive disorder
Agomelatine is used for the treatment of major depressive episodes in adults in Europe.Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder. At the end of treatment, significant efficacy was demonstrated in six of the ten short-term double-blind placebo-controlled studies.Two were considered "failed" trials, as comparators of established efficacy failed to differentiate from placebo. Efficacy was also observed in more severely depressed patients in all positive placebo-controlled studies.The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study.
In 2018, a systematic review and network meta-analysis comparing the efficacy and acceptability of 21 antidepressant drugs showed agomelatine to be one of the most effective and one of only two medications found to be more tolerable than placebo.
2.Generalized anxiety disorder
Agomelatine has been found more effective than placebo in the treatment of generalized anxiety disorder in a number of short-term double-blind placebo-controlled studies and in long term relapse prevention.
3.Use in special populations
It is not recommended in Europe for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy.However, a recent 12 week study first reported in September 2020, and published in 2022 showed greater efficacy vs. placebo for agomelatine 25 mg per day in youth age 7-17 years and an acceptable tolerability profile with similar efficacy to fluoxetine.Only limited data is available on use in elderly people ≥ 75 years old with major depressive episodes.It is not recommended during pregnancy or breastfeeding.
Tá go leor monarchana ardchaighdeáin againn le comhar domhain, ar féidir leo táirgí ardchaighdeáin agus praghsanna iomaíocha a sholáthar duit. Agus is féidir linn lascainí a thabhairt freisin le haghaidh ceannach mórchóir. Tá an t-am seachadta thart ar 3-20 lá tar éis an íocaíocht a dhaingniú.
Test based on USP 32 Standards. |
||
Test Items |
Caighdeáin |
Torthaí |
外观 Dealramh |
白色或类白色结晶性粉末 White to off white crystalline powder |
符合 Comhlíonann |
鉴别 Aitheantas |
在含量测定项下记录的色谱图中,供试品溶液主峰的保留时间应与对照品溶液主峰的保留时间一致 The retention time of the peak for alpha lipoic acid in the chromatogram of the assay preparation corresponds to that in the chromatogram of the standard preparation, as obtained in the assay. |
符合 Comhlíonann |
熔点 Melting point |
107~110℃ |
108.5℃ |
重金属 Miotail throma |
≤20ppm |
<10ppm |
干燥失重 Caillteanas ar thriomú |
≤0.5% |
0.4% |
灼烧残渣 ignition residue |
≤0.1% |
0.07% |
相关物质 Related compounds |
≤0.1% |
符合 Comhlíonann |
总杂质 Total impurities |
≤0.3% |
符合 Comhlíonann |
含量 Measúnacht |
99.0%~101.1% |
99.95% |
结论 Conclúid |
Confirms to Standards |
Agomelatine is a melatonergic antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder and has been reported to not produce discontinuation syndrome and have no sexual side effects compared to SSRIs, SNRIs and the older tricyclic antidepressants. Agomelatine may also have positive effects on sleep.
Iarratas
1) Agomelatine Improves Depressive Symptoms.
2) Agomelatine Lessens Anxiety, Stress, and PTSD and Symptoms From Stress.
3) Agomelatine Benefits Memory and Learning.
4) Agomelatine is an Anti-inflammatory.
5) Agomelatine decreases pain.
6) Agomelatine Helps Treat Irritable bowel Syndrome.
7) Agomelatine Reduces Asthma.
Catagóirí táirgí